Teva Pharmaceutical Industries Limited’s (TEVA) Innovative Brands Drive Stronger Growth
Baron Capital, an investment management company, released its Q3 2026 investor letter for the “Baron Health Care Fund”. The letter can be downloaded here.
Teva Pharmaceutical Industries Ltd (TEVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | 0 | $0 | 0% | ||
| 4. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% | |
| 5. | Bastion Asset Management Charles Haggar, Mathieu Boisvert, And Michael Gentile | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.86 | 1,113 | $20,988.06 | 13,027 | 2025-09-05 | Filing | |
| $9.60 | 104,500 | $1,003,409.00 | 220,442 | 2019-06-04 | Filing | |
| $8.98 | 111,000 | $997,013.10 | 115,942 | 2019-06-03 | Filing | |
| $21.92 | 2,000 | $43,840.00 | 6,445 | 2018-08-03 | Filing | |
| $19.32 | 250,000 | $4,829,700.00 | 1,500,000 | 2018-05-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $41.93 | 46,000 | $1,928,729.40 | 80,760 | 2026-11-05 | Filing | |
| $41.72 | 8,755 | $365,258.60 | 11,943 | 2026-11-04 | Filing | |
| $41.72 | 17,505 | $730,308.60 | 11,943 | 2026-11-04 | Filing | |
| $38.70 | 314 | $12,152.99 | 8,500 | 2026-09-18 | Filing | |
| $39.15 | 2,525 | $98,841.13 | 8,814 | 2026-09-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 39,422,212 | $1,561,119,595 | 9.6% | |
| 2. | 143,891 | $5,336,917 | 0.09% | |
| 3. | 76,883 | $3,060,712 | 0.01% | |
| 4. | 23,162 | $917,215 | 0.03% | |
| 5. | 20,400 | $691,152 | 0.03% |
News See All
Nvidia (NVDA) vs. Bumble (BMBL): How the AI Gold Rush is Blinding Investors to Real-Value Gems
The financial markets are currently gripped by a singular obsession: artificial intelligence.
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs
Hardman Johnston Global Advisors, an investment management firm, issued its Q3 2026 investor letter for the "Hardman Johnston International Equity Developed Markets Strategy".
Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries' (TEVA) Margin Expansion
TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the “TCW Relative Value Mid Cap Fund”. The letter can be downloaded here.
Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc.
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics...
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute.
TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer
Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome m...
Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best low-priced pharma stocks on this list.
12 Best Low-Priced Pharma Stocks to Buy Right Now
In this article, we will be taking a look at the 12 Best Low-Priced Pharma Stocks to Buy Right Now.
Hedge Fund Resource Center